Search for European Projects

16 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Eliciting Mucosal Immunity to Tuberculosis (EMI-TB)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis ...
Read Project

 15

 FINISHED 

European Research Infrastructures for Poverty Related Diseases (EURIPRED)

Start date: Nov 1, 2013, End date: Oct 31, 2017,

HIV/AIDS, Tuberculosis (TB) and Malaria alone account for more than six million deaths worldwide every year. Despite substantial efforts made in recent years, Poverty Related Diseases are still spreading. New therapeutic interventions are therefore urgently required to combat Poverty Related Diseases. The existence of a well-developed HIV/TB/Malaria infrastructure presents a prime opportunity to a ...
Read Project

 18

 FINISHED 

Industrial innovations based on EU intellectual property assets in the field of atmospheric plasma technology (IP4PLASMA)

Start date: Jan 1, 2014, End date: Dec 31, 2016,

The IP4Plasma project aims to bridge the gap between IPR protected laboratory-scale innovations in the field of atmospheric pressure plasma assisted chemical vapour deposition (AP-PA-CVD) technology and its industrial implementation for advanced surface treatment and nano-scale coating of materials. This will be done by demonstrating the suitability of the technology for existing and new industria ...
Read Project

 9

 FINISHED 

"Multimodular biomarker analysis workflow for diagnosis, prognosis and monitoring of drug treatment response in bladder cancer" (DIPROMON)

Start date: Nov 1, 2012, End date: Oct 31, 2016,

"With the advent of Omics technologies capable of profiling substantial fractions of molecular entities from the genome down to the metabolome level a significant boost in understanding disease pathophysiology, consequently providing tailored diagnostics and therapy, was expected. With impressive results for selected diseases, cancer still sees significant shortcomings. One reason for this clinica ...
Read Project

 6

 FINISHED 

Development of a low-cost point-of-care test for Tuberculosis detection (Pocket)

Start date: Nov 1, 2013, End date: Oct 31, 2016,

Pocket will develop a novel point-of-care (PoC) urine test for the detection of tuberculosis (TB), achieving at the same time a low cost (5 to 10 euro end-user cost per test, including depreciation cost of the instrument) and a high accuracy (>80% capture of TB-positive patients, which is much better than the present solutions which reach 60%). The test positions itself between current low-end imm ...
Read Project

 6

 FINISHED 

Development of RApid Point-of-Care test Platforms for Infectious Diseases (RAPP-ID)

Start date: Apr 1, 2011, End date: Sep 30, 2016,

RAPP-ID (“Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital
Read Project

 20

 FINISHED 

Fast, cost-effective, user-friendly point of care (POC) instrument for detection of respiratory pathogens, including Streptococcus pneumoniae (RESPOC)

Start date: Dec 1, 2013, End date: Aug 31, 2016,

Molecular techniques such as PCR (polymerase chain reaction) are becoming increasingly used for the detection of respiratory pathogens, due to their high accuracy and relatively fast turnaround time (hours). Their utilization can result in early and specific treatment, contribute to better patient outcomes and reduce length of hospital stay. However, implementation of rapid molecular diagnostics r ...
Read Project

 8

 FINISHED 

Demonstration of NOPERSIST results leading to novel, validated diagnostic tests for active human and bovine tuberculosis (DEMO-NOPERSIST)

Start date: Oct 1, 2013, End date: Sep 30, 2015,

...y countries (e.g. UK, Ireland, France, Austria, Germany).The specific objectives achievable within DEMO-NOPERSIST project are1. Development and evaluation of prototype test kits for active human TB (LIONEX, SME). This test shall be the World’s first blood test for discriminating latent from active TB in humans.2. Development and evaluation of prototype test kits for active Bovine TB (PRIONICS, SM ...
Read Project

 4

 FINISHED 

Systems biology of Mycobacterium tuberculosis (SYSTEMTB)

Start date: Apr 1, 2010, End date: Sep 30, 2014,

Tuberculosis (TB) is a re-emerging global health threat caused by Mycobacterium tuberculosis (Mtb). One third of the world's population is infected with Mtb and new infections occur at a rate of one per second. Despite global research efforts, mechanisms underlying pathogenesis, virulence and persistence of Mtb infection remain poorly understood. Simple reductionist approaches are insufficient to ...
Read Project

 14

 FINISHED 

European Network of Vaccine Development and Research (TRANSVAC)

Start date: Oct 1, 2009, End date: Sep 30, 2013,

"The TRANSVAC infrastructure will accelerate the pharmaceutical and clinical development of promising vaccine candidates by bringing the gap between academic research and clinical trials through carefully managing the advancement of promising vaccine candidates from preclinical animal models to early proof-of-principle studies in humans. Although expertise already exists within Europe spanning dif ...
Read Project

 18

 FINISHED 

"Early detection of HIV-1 using ultra-sensitive, rapid capacitive biosensor" (CAPHIV)

Start date: Sep 1, 2011, End date: Sep 30, 2013,

"The HIV pandemic continues to be a worldwide public-health problem. The virus, which is spread through sexual contact, exposure to infected blood, or through shared syringes, is highly infective, rapidly mutates, and has no cure. Because there is no effective vaccine or other prophylaxis available, the current best practice and standard of care for those infected is an early, accurate diagnosis ...
Read Project

 7

 FINISHED 

Identification and development of vaccine candidates for Buruli Ulcer Disease (BuruliVac)

Start date: Mar 1, 2010, End date: May 31, 2013,

Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly affecting children. BUD, the third most common mycobacterial disease in immunocompetent humans after tuberculosis and leprosy, is most endemic in West Africa, but cases have been reported from more than 30 countries. BUD is a mutilating disease leading to sever ...
Read Project

 16

 FINISHED 

Novel strategies for the prevention and control of persistent infections (NOPERSIST)

Start date: Jan 1, 2010, End date: Dec 31, 2012,

... is no effective vaccine available against the persistent infections addresses in this proposal. The four SME members of this consortium with complimentary areas of research and business activities, LIONEX (in TB), Prionics (in ParaTB) , Vichem (in HIV) and IVD (in pig infections) are dedicated to solving the problems of the persistent infections mentioned above by employing novel strategies of pr ...
Read Project

 12

 FINISHED 

"The identification, characterisation and exploitation of novel Gram-negative drug targets." (AEROPATH)

Start date: Nov 1, 2008, End date: Oct 31, 2012,

"An ambitious long-term programme of multidisciplinary research with two closely linked objectives is proposed to support antimicrobial drug development. Firstly, to advance understanding, at the molecular level, of fundamental and important aspects of the biology of Gram-negative bacteria using the important pathogen model Pseudomonas aeruginosa. Secondly, and most important, to exploit our disco ...
Read Project

 5

 FINISHED 

Host and microbial molecular dissection of pathogenesis and immunity in tuberculosis (HOMITB)

Start date: Nov 1, 2008, End date: Apr 30, 2012,

"Tuberculosis (TB) is a leading public health problem. About half of the 10% of Mycobacterium tuberculosis-infected individuals develop overt clinical disease, do so within two years of primary infection. The remaining half of the TB patients, develop clinical disease later, owing to “reactivation” of pulmonary TB. Of importance, it is not understood why only 10% infected individuals develop activ ...
Read Project

 9

 FINISHED 

Development of a two-approach plate system for the fast and simultaneous detection of MDR and XDR M. tuberculosis (FAST-XDR-DETECT)

Start date: Feb 1, 2008, End date: Jan 31, 2012,

Tuberculosis (TB) continues being a leading cause of death due to a single infectious disease agent. The HIV/AIDS pandemic and the emergence of drug resistance are compounding factors that hinder the control of the disease. Associated with this problem is the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, defined as strains resistant to at least isoniazid and rifampi ...
Read Project

 8